Metabolic response by FDG PET-CT and its correlation with pathological response and genomic profile in patients of Non-Small Cell Lung Cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy - NI

AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•Age 18-75 years Pathological diagnosis of NSCLC in Stage 2B or 3A . Being considered for neoadjuvant chemotherapy followed by surgery after discussion in MDT. Complete surgical removal should be deemed achievable including surgical fitness. ECOG (Eastern Cooperative Oncology Group) performance score 0to1. Adequate organ functions and marrow functions as described below
•A. Serum creatinine less than equal to 1.5 mg or creatinine clearance more than equal 50 ml/min. B. Serum Bilirubin less than 1.5 UNL, ASTor ALT less than 3 UNL C. Hb more than 10.0 gmdl, Platelet counts more than 100 x10 9 L, absolute neutrophil count more than 1.5 X10 9L Able to understand the PIS (patient information sheet and give informed consent)

•ECOG performance score more or equal to 2 .Harboring EGFR mutations, ALK and ROS1 rearrangements.Prior exposure to immune checkpoint inhibitors. Pre-existing autoimmune condition requiring systemic immunosuppression including steroids (more than 10 mg Prednisolone equivalent).
•Acquired immunosuppression (HIV, systemic immunosuppression)
•.Hematopoietic or organ transplant recipient. History of any other malignancy in past or synchronous malignancy.Pregnant and lactating mothers. Willing to afford or have access to immunotherapy outside study.Patients with any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or compromise the patient’s ability to participate in this study.Uncontrolled diabetes mellitus with fasting plasma glucose persistently above 200 mgdl which could compromise the patient’s ability to undergo FDG PET-CT scan.

发起方

AIIMS New Delhi